Cargando…
The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease
BACKGROUND AND PURPOSE: The polypill approach has been proposed to reduce patients’ pill burden, increase medication adherence and lower stroke incidence. However, little is known about patients’ attitudes towards polypills for cerebrovascular medication. METHODS: Based on the European Organization...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292587/ https://www.ncbi.nlm.nih.gov/pubmed/34463018 http://dx.doi.org/10.1111/ene.15088 |
_version_ | 1784749408327303168 |
---|---|
author | Lehmann, Jens Riedl, David Sztankay, Monika Boehme, Christian Fischnaller, Julian Kiechl, Stefan Holzner, Bernhard Knoflach, Michael Rumpold, Gerhard |
author_facet | Lehmann, Jens Riedl, David Sztankay, Monika Boehme, Christian Fischnaller, Julian Kiechl, Stefan Holzner, Bernhard Knoflach, Michael Rumpold, Gerhard |
author_sort | Lehmann, Jens |
collection | PubMed |
description | BACKGROUND AND PURPOSE: The polypill approach has been proposed to reduce patients’ pill burden, increase medication adherence and lower stroke incidence. However, little is known about patients’ attitudes towards polypills for cerebrovascular medication. METHODS: Based on the European Organization for Research and Treatment of Cancer Quality of Life Group questionnaire development guidelines, a questionnaire to measure patients’ attitudes towards polypills for the secondary prevention of stroke (phase I–III) was developed. In phase I, issues were generated via literature review and interviews with patients and healthcare professionals. The issues were operationalized into items in phase II. In phase III the questionnaire was validated in a large single‐centre sample, and test–retest and internal validity were evaluated. RESULTS: In phase I, 34 relevant issues were identified through literature search and interviews. Pre‐testing the questionnaire indicated high applicability and comprehensibility. The final Attitudes towards Polypills Questionnaire was tested in N = 260 patients and showed a two‐factor structure. The factors were labelled ‘concerns’ and ‘benefits’. The scales showed acceptable and good internal validity (concerns, Cronbach's α = 0.85; benefits, α = 0.93), but the scales’ test–retest validity was ambiguous. On a 0 to 3 rating scale, concerns were rated lower than benefits (mean 1.07, SD 0.69 vs. mean 1.87, SD 0.89). CONCLUSIONS: The Attitudes towards Polypills Questionnaire showed high comprehensibility and content validity to assess German language patients’ attitudes towards a polypill medication. Our data and questionnaire may aid the implementation of polypill treatments in clinical practice and can be used in the design of future clinical trials on polypill therapy. Further validation of the questionnaire is advised. |
format | Online Article Text |
id | pubmed-9292587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92925872022-07-20 The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease Lehmann, Jens Riedl, David Sztankay, Monika Boehme, Christian Fischnaller, Julian Kiechl, Stefan Holzner, Bernhard Knoflach, Michael Rumpold, Gerhard Eur J Neurol Stroke BACKGROUND AND PURPOSE: The polypill approach has been proposed to reduce patients’ pill burden, increase medication adherence and lower stroke incidence. However, little is known about patients’ attitudes towards polypills for cerebrovascular medication. METHODS: Based on the European Organization for Research and Treatment of Cancer Quality of Life Group questionnaire development guidelines, a questionnaire to measure patients’ attitudes towards polypills for the secondary prevention of stroke (phase I–III) was developed. In phase I, issues were generated via literature review and interviews with patients and healthcare professionals. The issues were operationalized into items in phase II. In phase III the questionnaire was validated in a large single‐centre sample, and test–retest and internal validity were evaluated. RESULTS: In phase I, 34 relevant issues were identified through literature search and interviews. Pre‐testing the questionnaire indicated high applicability and comprehensibility. The final Attitudes towards Polypills Questionnaire was tested in N = 260 patients and showed a two‐factor structure. The factors were labelled ‘concerns’ and ‘benefits’. The scales showed acceptable and good internal validity (concerns, Cronbach's α = 0.85; benefits, α = 0.93), but the scales’ test–retest validity was ambiguous. On a 0 to 3 rating scale, concerns were rated lower than benefits (mean 1.07, SD 0.69 vs. mean 1.87, SD 0.89). CONCLUSIONS: The Attitudes towards Polypills Questionnaire showed high comprehensibility and content validity to assess German language patients’ attitudes towards a polypill medication. Our data and questionnaire may aid the implementation of polypill treatments in clinical practice and can be used in the design of future clinical trials on polypill therapy. Further validation of the questionnaire is advised. John Wiley and Sons Inc. 2021-09-09 2021-12 /pmc/articles/PMC9292587/ /pubmed/34463018 http://dx.doi.org/10.1111/ene.15088 Text en © 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Stroke Lehmann, Jens Riedl, David Sztankay, Monika Boehme, Christian Fischnaller, Julian Kiechl, Stefan Holzner, Bernhard Knoflach, Michael Rumpold, Gerhard The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease |
title | The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease |
title_full | The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease |
title_fullStr | The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease |
title_full_unstemmed | The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease |
title_short | The Attitude towards Polypills Questionnaire (APPQ): a phase I–III development and validation study in patients with cerebrovascular disease |
title_sort | attitude towards polypills questionnaire (appq): a phase i–iii development and validation study in patients with cerebrovascular disease |
topic | Stroke |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292587/ https://www.ncbi.nlm.nih.gov/pubmed/34463018 http://dx.doi.org/10.1111/ene.15088 |
work_keys_str_mv | AT lehmannjens theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT riedldavid theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT sztankaymonika theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT boehmechristian theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT fischnallerjulian theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT kiechlstefan theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT holznerbernhard theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT knoflachmichael theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT rumpoldgerhard theattitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT lehmannjens attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT riedldavid attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT sztankaymonika attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT boehmechristian attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT fischnallerjulian attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT kiechlstefan attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT holznerbernhard attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT knoflachmichael attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease AT rumpoldgerhard attitudetowardspolypillsquestionnaireappqaphaseiiiidevelopmentandvalidationstudyinpatientswithcerebrovasculardisease |